<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954824</url>
  </required_header>
  <id_info>
    <org_study_id>706771</org_study_id>
    <secondary_id>1R01HL073278-01</secondary_id>
    <nct_id>NCT00954824</nct_id>
  </id_info>
  <brief_title>Inflammation and the Metabolic Syndrome in Humans</brief_title>
  <acronym>LPS</acronym>
  <official_title>Inflammation and the Metabolic Syndrome in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People who are overweight are at increased risk of heart disease. Being overweight and having
      heart disease are linked in that both involve inflammation. Inflammation refers to the body's
      first line of defense against infection and injury. Metabolic changes in cholesterol,
      triglycerides (fat in the blood) and sugar in the blood caused by inflammation are similar to
      that in some people who are overweight. The investigators wish to examine the effects of
      inflammation on these metabolic changes that may lead to heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single site, open-label, &quot;baseline-controlled&quot; (pre LPS saline period) study
      examining the pro-atherosclerotic metabolic responses and safety responses to a single
      administration low-dose (3 ng/kg) endotoxin (LPS) in 20 additional non-metabolic syndrome
      participants: 10 healthy overweight and 10 healthy lean counterparts (20 non-metabolic
      syndrome participants were studies in first phase), and 40 subjects with the metabolic
      syndrome. We are continuing to use an approach whereby &quot;metabolic syndrome&quot; subjects will be
      recruited to have key metabolic syndrome abnormalities that are sensitive to insulin
      resistance compared to the non-metabolic syndrome groups, although all of these &quot;metabolic
      syndrome&quot; subjects may not fulfill traditional NCEP criteria for the syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure is Plasma Levels of TNF Alpha.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Endotoxin (LPS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration low-dose (3 ng/kg) endotoxin (LPS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endotoxin (LPS)</intervention_name>
    <description>Single administration low-dose (3 ng/kg) endotoxin (LPS).</description>
    <arm_group_label>Endotoxin (LPS)</arm_group_label>
    <other_name>LPS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and non-pregnant/lactating women between the ages of 18 and 40

          2. Subjects must be able to give written informed consent and willing to comply with all
             study-related procedures.

          3. BMI &gt;18 and &lt; 24 and BIA &lt; 15% fat for men, &lt; 25% fat for women, and do not have
             diagnosis of NCEP metabolic syndrome as defined below, OR

          4. BMI &gt; 26 but &lt; 30 and BIA &gt; 15% fat for men, &gt; 25% fat for women, do not have
             diagnosis of NCEP metabolic syndrome, OR

          5. BMI &gt;18 and &lt; 30 and have metabolic syndrome abnormalities as defined below. The
             modified NCEP Metabolic Syndrome criteria are as follows

               -  abdominal obesity, waist circumference: men &gt;= 37 in (94 cm), women &gt;= 31 in (80
                  cm)

               -  fasting triglycerides &gt; 150 mg/dL

               -  HDL cholesterol &lt; 40 mg/dL for men; HDL cholesterol &lt; 50 mg/dL for women

               -  Blood pressure &gt; 130/ &gt;85 mmHg in untreated patients

               -  Fasting glucose &gt; 100 mg/dL, but less than 126 mg/dL

          6. For inclusion in &quot;metabolic syndrome&quot; group, the following additional criteria must be
             fulfilled:

               -  Three or more of the NCEP criteria defined above. OR

               -  Two or more of the NCEP criteria AND TG/HDL ratio &gt; 3.0.

        Exclusion Criteria:

          1. Known atherosclerotic cardiovascular disease, including coronary disease,
             cerebrovascular disease, or peripheral vascular disease.

          2. History of diabetes mellitus.

          3. A plasma glucose greater than 200 mg/dL at the 2 hour blood draw of the oral glucose
             tolerance test.

          4. History of a non-skin malignancy within the previous 5 years.

          5. Renal insufficiency as defined by creatinine &gt;= 1.5 mg/dl at visit 1 (grade 1 of NIH's
             Common Toxicity Criteria (CTC), version 2.0, 4/30/99).

          6. History of liver disease or ALT, AST, ALK Phosphatase or Gamma GT above normal limits
             as defined by HUP William Pepper Clinical Laboratory at visit 1.

          7. Elevated (&gt; 1.5x ULN; grade 1, CTC, 4/30/99) Total Bilirubin or LDH at visit 1.

          8. Men who consume &gt; 14 alcoholic drinks per week or &gt; 4 alcoholic drinks per occasion
             (AMA/NIAAA criteria for &quot;at risk&quot; usage levels).

          9. Women who consume &gt; 7 alcoholic drinks per week or &gt; 3 alcoholic drinks per occasion
             (AMA/NIAAA criteria for &quot;at risk&quot; usage levels).

         10. Total white blood cell count below normal limits as defined at HUP William Pepper
             Clinical Laboratory prior to the baseline visit.

         11. Hemoglobin below normal limits (gender specific) as defined at HUP William Pepper
             Clinical Laboratory prior to the baseline visit.

         12. Any medical condition or abnormal laboratory value that is judged clinically
             significant by an investigator.

         13. Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory
             condition or minor active infection.

         14. History of HIV positive.

         15. First degree family history of premature cardiovascular disease event (father or
             brother if diagnosed at before 55 years of age; mother or sister if diagnosed before
             65 years of age).

         16. Patients who have undergone any organ transplant.

         17. Individuals who currently use tobacco products or have done so in the previous 30
             days.

         18. Treatment with aspirin, NSAIDs, COX-2 inhibitors, steroids or other immunomodulatory
             therapy 2 weeks prior to the screening visit

         19. Treatment with statins, fibrates or niacin 4 weeks prior to the screening visit.

         20. Current daily use of Vitamin C &gt; 1000 mg, Beta carotene &gt; 1000 IU, vitamin A &gt; 5000
             IU, vitamin E &gt; 400 IU, and selenium &gt; 200 mcg.

         21. Positive urine pregnancy at the screening visit.

         22. Participation in another clinical trial within the previous 6 weeks prior to the
             screening visit.

         23. Poorly controlled blood pressure (BP &gt; 160/100) or on any anti-hypertensive
             medications.

         24. For subjects in non-metabolic syndrome groups; a diagnosis of metabolic syndrome using
             NCEP ATPIII criteria.

         25. For subjects in &quot;metabolic syndrome&quot; group; an abnormal Bruce protocol cardiac
             exercise stress test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muredach P. Reilly, MB, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Translational Research Center, Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS, Reilly MP. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007 Jun;92(6):2272-9. Epub 2007 Mar 20.</citation>
    <PMID>17374708</PMID>
  </reference>
  <reference>
    <citation>Heffron SP, Parastatidis I, Cuchel M, Wolfe ML, Tadesse MG, Mohler ER 3rd, Ischiropoulos H, Rader DJ, Reilly MP. Inflammation induces fibrinogen nitration in experimental human endotoxemia. Free Radic Biol Med. 2009 Oct 15;47(8):1140-6. doi: 10.1016/j.freeradbiomed.2009.07.025. Epub 2009 Jul 22.</citation>
    <PMID>19631267</PMID>
  </reference>
  <reference>
    <citation>Shah R, Lu Y, Hinkle CC, McGillicuddy FC, Kim R, Hannenhalli S, Cappola TP, Heffron S, Wang X, Mehta NN, Putt M, Reilly MP. Gene profiling of human adipose tissue during evoked inflammation in vivo. Diabetes. 2009 Oct;58(10):2211-9. doi: 10.2337/db09-0256. Epub 2009 Jul 6.</citation>
    <PMID>19581417</PMID>
  </reference>
  <reference>
    <citation>McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009 Mar 3;119(8):1135-45. doi: 10.1161/CIRCULATIONAHA.108.810721. Epub 2009 Feb 16.</citation>
    <PMID>19221221</PMID>
  </reference>
  <reference>
    <citation>Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase is increased in vivo by inflammation in humans. Circulation. 2008 Feb 5;117(5):678-85. doi: 10.1161/CIRCULATIONAHA.107.707349. Epub 2008 Jan 22.</citation>
    <PMID>18212282</PMID>
  </reference>
  <reference>
    <citation>Song WL, Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, Reilly M, Lawson JA, FitzGerald GA. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem. 2008 Jan 11;283(2):1179-88. Epub 2007 Nov 8.</citation>
    <PMID>17993463</PMID>
  </reference>
  <reference>
    <citation>Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol. 2007 Jan 30;49(4):442-9. Epub 2007 Jan 12.</citation>
    <PMID>17258089</PMID>
  </reference>
  <reference>
    <citation>Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005 Feb 22;111(7):932-9. Epub 2005 Feb 14.</citation>
    <PMID>15710760</PMID>
  </reference>
  <reference>
    <citation>Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 2004 Nov;1(2):e45. Epub 2004 Nov 30. Review.</citation>
    <PMID>15578112</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <results_first_submitted>August 17, 2015</results_first_submitted>
  <results_first_submitted_qc>December 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2016</results_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Non-tobacco using individuals between ages 18-40 in 2 groups- with metabolic syndrome (having 3 of 5 criteria) and non-metabolic syndrome.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Endotoxin (LPS)</title>
          <description>Single administration low-dose (3 ng/kg) endotoxin (LPS).
Endotoxin (LPS): Single administration low-dose (3 ng/kg) endotoxin (LPS).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Endotoxin (LPS)</title>
          <description>Single administration low-dose (3 ng/kg) endotoxin (LPS).
Endotoxin (LPS): Single administration low-dose (3 ng/kg) endotoxin (LPS).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" lower_limit="19" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure is Plasma Levels of TNF Alpha.</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotoxin (LPS)</title>
            <description>Single administration low-dose (3 ng/kg) endotoxin (LPS).
Endotoxin (LPS): Single administration low-dose (3 ng/kg) endotoxin (LPS).</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Measure is Plasma Levels of TNF Alpha.</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507" spread="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Endotoxin (LPS)</title>
          <description>Single administration low-dose (3 ng/kg) endotoxin (LPS).
Endotoxin (LPS): Single administration low-dose (3 ng/kg) endotoxin (LPS).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HR &lt; 50bpm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rigors</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vagal reaction</sub_title>
                <description>also termed vaso-vagal events or syncope</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>superficial thrombophlebitis</sub_title>
                <description>from IV site used over the course of inpatient visit</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Muredach Reilly</name_or_title>
      <organization>UPenn</organization>
      <phone>215-573-1214</phone>
      <email>muredach@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

